Circulating endothelial cells and circulating progenitor cells in breast cancer: Relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham prognostic index

Neoplasia

Volumn 11, Issue 8, 2009, Pages 771-779

  Goon, Patrick K Y ^a   Lip, Gregory Y H ^a   Stonelake, Paul S ^b   Blann, Andrew D ^a,c  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; CD133 ANTIGEN; CD146 ANTIGEN; CD34 ANTIBODY; CD45 ANTIGEN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL; TUMOR VOLUME;

EID: 67650474132     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09490     Document Type: Article

References (59)

1. Blann AD,Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, et al. (2005). Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 93, 228-235.
2. Goon PK, Lip GY, Boos CJ, Stonelake PS, and Blann AD (2006). Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8, 79-88.
3. Wojakowski W, Kucia M, Kaźmierski M, Ratajczak MZ, and Tendera M (2008). Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart 94, 27-33.
4. Ergün S, Hohn HP, Kilic N, Singer BB, and Tilki D (2008). Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem Cell Rev 4, 169-177.
5. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K,Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, et al. (2005). Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11, 261-262.
6. Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, Lang G,Dome P, Bogos K, and Tovari J (2009). Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol 69, 108-124.
7. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, et al. (2007). Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28, 1067-1073.
8. Gehling UM, Ergün S, Schumacher U,Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, et al. (2000). In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95, 3106-3112.
9. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, and Verfaillie CM (2002). Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 109, 337-346.
10. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, and Deliliers GL (2001). Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 115, 186-194.
11. + cells in vitro. Acta Pharmacol Sin 24, 212-218.
12. Aoki M, Yasutake M, and Murohara T (2004). Derivation of functional endothelial progenitor cells from human umbilical cord blood mononuclear cells isolated by a novel cell filtration device. Stem Cells 22, 994-1002.
13. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, and Griffiths K (1982). A prognostic index in primary breast cancer. Br J Cancer 45, 361-366.
14. Caine GJ, Blann AD, Stonelake PS, Ryan P, and Lip GYH (2003). Plasma angiopoietin-1, angiopoietin-2 and tie-2 in breast and prostate cancer: a comparison with VEGF and flt-1. Eur J Clin Invest 33, 883-890.
15. Duranyildiz D, Camlica H, Soydinc HO, Derin D, and Yasasever V (2009). Serum levels of angiogenic factors in early breast cancer remain close to normal. Breast 18, 26-29.
16. Nierodzik ML, Klepfish A, and Karpatkin S (1995). Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 74, 282-290.
17. Blann AD (2006). Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 95, 49-55.
18. Song RX and Santen RJ (2003). Apoptotic action of estrogen. Apoptosis 8, 55-60.
19. Boos CJ, Balakrishnan B, Blann AD, and Lip GY (2008). The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 6, 1841-1850.
20. Goon PKY, Boos CJ, Stonelake PS, Blann AD, and Lip GYH (2006). Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost 96, 45-52.
21. Goon PKY, Watson T, Shantsila E, Boos CJ, and Lip GYH (2007). Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. J Thromb Haemost 5, 870-872.
22. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, and Voest EE (2004). Increased levels of viable of circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15, 139-145.
23. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, and Bertolini F (2001). Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97, 3658-3661.
24. Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, Hamacher J, and Boneberg EM (2006). Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94, 524-531.
25. Goodale D, Phay C, Brown W, Gray-Statchuk L, Furlong P, Lock M, Chin-Yee I, Keeney M, and Allan AL (2009). Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry B Clin Cytom 76, 107-117.
26. Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A, et al. (2006). Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66, 7341-7347.
27. Kim HK, Song KS, Kim HO, Chung JH, Lee KR, Lee YJ, Lee DH, Lee ES, Kim HK, Ryu KW, et al. (2003). Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. Cancer Lett 198, 83-88.
28. Richter-Ehrenstein C, Rentzsch J, Runkel S, Schneider A, and Schönfelder G (2007). Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat 106, 343-349.
29. Naik RP, Jin D, Chuang E, Gold EG, Tousimis EA, Moore AL, Christos PJ, de Dalmas T, Donovan D, Rafii S, et al. (2008). Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 107, 133-138.
30. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, et al. (2008). VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14, 7871-7877.
31. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, and Jain RK (2006). Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24, 1449-1453.
32. Wu GJ, Peng Q, Fu P, Wang SW, Chiang CF, Dillehay DL, and Wu MW(2004). Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 327, 201-213.
33. Kristiansen G, Yu Y, Schlüns K, Sers C, Dietel M, and Petersen I (2003). Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol 25, 77-81.
34. Garcia S, Dalès JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, et al. (2007). Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 38, 830-841.
35. Jacques N, Vimond N, Conforti R, Griscelli F, Lecluse Y, Laplanche A, Malka D, Vielh P, and Farace F (2008). Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J Immunol Methods 337, 132-143.
36. Urbich C and Dimmeler S (2004). Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95, 343-353.
37. + blood cells. Thromb Haemost 94, 1270-1279.
38. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, and Kanz L (1995). Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333, 283-287.
39. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, et al. (2000). Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95, 952-958.
40. Hristov M and Weber C (2004). Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 8, 498-508.
41. Vroling L, Yuana Y, Schuurhuis GJ, van Hinsbergh VW, Gundy C, de Haas R, van Cruijsen H, Boven E, Hoekman K, and Broxterman HJ (2007). VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. Thromb Haemost 98, 440-450.
42. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, et al. (2005). Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 23, 1379-1389.
43. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, and White E (1999). Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screendetected cancers. J Natl Cancer Inst 91, 2020-2028.
44. London SJ, Colditz GA, Stampfer MJ, Willett WC, Rosner BA, and Speizer FE (1989). Prospective study of smoking and the risk of breast cancer. J Natl Cancer Inst 81, 1625-1631.
45. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, Inden Y, and Murohara T (2004). Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 24, 1442-1447.
46. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, Martinelli G, Shultz L, and Bertolini F (2003). Continuous infusion of endostatin inhibits differentiation, mobilization and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9, 377-382.
47. Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, et al. (1998). Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of nodenegative breast cancer patients. J Clin Oncol 16, 3129-3136.
48. Caine GJ, Lip G, Zanetto U,Maheshwari M, Stonelake PS, and Blann AD (2007). A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. Appl Immunohistochem Mol Morphol 15, 382-388.
49. Sheen-Chen SM, Eng HL, Chen WJ, Chou FF, and Chen HS (2000). Serum level of angiogenin in breast cancer. Anticancer Res 20, 4769-4771.
50. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, and Isner JM (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18, 3964-3972.
51. Caine GJ, Stonelake PS, Lip GY, and Blann AD (2007). Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Lett 248, 131-136.
52. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, and Nickenig G (2005). Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353, 999-1007.
53. Mollinedo F and Gajate C (2006). Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat 9, 51-73.
54. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, et al. (2008). Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26, 4899-4905.
55. Pearson JD (2009). Endothelial progenitor cells-hype or hope? J Thromb Haemost 7, 255-262.
56. Hirschi KK, Ingram DA, and Yoder MC(2008). Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28, 1584-1595.
57. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, et al. (2009). Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15, 267-273.
58. Mancuso P, Colleoni M, Calleri A, Orlando L,Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, et al. (2006). Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452-459.
59. Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, et al. (2008). Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99, 1564-1571.